Steven Hunt, MD
Colon & Rectal Surgery · Saint Louis, MONPI 1205853835
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (34.5%), speaking fees and education — rather than concentrated in one kind of arrangement. Arthrex accounts for 66.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $11,001 and has fallen 88.8% since, to $1,228 in 2025.
Across 48 payments — averaging $350.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$11K
- Intuitive Surgical$5K
- Stryker$195
- Medtronic$191
- Davol Inc.$178
- KARL Storz Endoscopy-america$157
- plus $329 from 5 others
What the payments were for
- Consulting fees$5,80034%
- Speaking & faculty fees$3,48021%
- Travel & lodging$2,40514%
- Food & beverage$2,14613%
- Education$3,00018%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 18 | $11,126 |
| Intuitive Surgical | 14 | $4,654 |
| Stryker | 3 | $195 |
| Medtronic | 2 | $191 |
| Davol Inc. | 1 | $178 |
| KARL Storz Endoscopy-america | 4 | $157 |
| Genmab U.S., Inc. | 1 | $114 |
| Northgate Technologies, Inc. | 2 | $93 |
| Dilon Technologies, Inc. | 1 | $63 |
| Covidien LP | 1 | $36 |
| Elite Orthopedics, LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,265
- Signia$169
- TIVDAK$114
- SPY TECHNOLOGY$100
How this compares
$16,831 in reported general payments places this provider in the 85th percentile of 36 colon & rectal surgery providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 81 | $5,253 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 19 | $840 |
| LoperamideLoperamide Hcl | 20 | $562 |
| Neomycin Sulfate | 111 | $557 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $337 |
| Metronidazole | 114 | $292 |
| Ondansetron OdtOndansetron | 67 | $132 |
| Oxycodone Hcl | 29 | $109 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Saint Louis
- Lawrence MendelowSaint Louis$234K
- Paul WiseSaint Louis$24K
- Donald SummersSaint Louis$22K
- Tatiana Ramirez DominguezSaint Louis$12K
- Eric LedermanSaint Louis$11K
- Patrick ChizekSaint Louis$8K
- Alyssa WaitSaint Louis$6K
- Kathryn GalieSaint Louis$6K
- Sean GlasgowSaint Louis$6K
- William ChapmanSaint Louis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.